Zusammenfassung
Berichte über die geringe Wirksamkeit einer Chemotherapie in der Behandlung des metastasierten Nierenzellkarzinoms (NZK) haben zur Suche nach effektiven Alternativen geführt. Vor allem die Immuntherapie hat in den letzten 10 Jahren zunehmend an Bedeutung gewonnen. Sie wird in einigen Lehrbüchern bereits als anerkanntes Therapiekonzept dargestellt. Ziel des vorliegenden Beitrags ist eine kurze Analyse, ob die Immuntherapie in der derzeit praktizierten Form tatsächlich einen Stellenwert in der Behandlung des metastasierten NZK hat.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Decken K, Schmitz-Dräger BJ, Rohde D, Nakamura S, Ebert T, Ackermann R (1992) Monoclonal antibody due ABC 3 directed against transitional cell carcinoma. I. Production, specificity analysis, and preliminary characterization of the antigen. J Urol 147: 235
Fojo AT, Shen DW, Mickley LA, Pastan IA, Gottesman MM (1987) Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug resistance gene. J Clin Oncol 5: 1922
Fossa SD, Gunderson R, Moe B (1990) Recombinant interferon-alpha combined with prednisone in metastatic renal cell carcinom: reduced toxicity without reduction of the response rate — a phase II study. Cancer 11: 2451
Koretz MJ, Lawson DH, York RM et al. (1991) Randomized study of interleukin 2 (IL-2) alone vs. IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer. Arch Surg 126: 898
Maldazys JD, DeKernion JB (1986) Prognostic factors in metastatic renal cell carcinoma. J Urol 136: 376
McCabe MS, Stablein D, Hawkins MJ (1991) The modified group C experience — Phase III randomized trials of IL-2 vs. IL-2/LAK in advanced renal cell carcinoma and advanced melanoma. Proc ASCO 10: 212
Nanus DM, Pfeffer LM, Bander NH et al. (1990) Antiproliferative and antitumor effects of α-interferon in renal cell carcinomas: correlation with the expression of a kidneyassociated differentiation glycoprotein Cancer Res 50: 4190
Rosenberg SA, Lotze MT, Muul LM et al. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316: 889
Schmitz-Dräger BJ, Rohde D, Decken K et al. (1991) The prognostic significance of a carbohydrate antigen (ABC 3 antigen) in renal cell carcinoma, (to be published)
Tomita Y, Nishiyama T, Watanabe H, Fujiwara M, Sato S (1990) Expression of intercellular adhesion molecule-1 (ICAM-1) on renal-cell cancer: possible significance in host immune response. Int J Cancer 46: 1001
Yagoda A (1989) Chemotherapy of renal cell carcinoma. Semin Urol VII: 199
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Schmitz-Dräger, B.J., Ebert, T. (1993). Überlegungen zur Immuntherapie beim metastasierten Nierenzellkarzinom. In: Rübben, H., Goepel, M., Schmitz-Dräger, B.J. (eds) Immuntherapie in der Uroonkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77830-8_33
Download citation
DOI: https://doi.org/10.1007/978-3-642-77830-8_33
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-77831-5
Online ISBN: 978-3-642-77830-8
eBook Packages: Springer Book Archive